Papers on amylin

83 papers7 new in 30 days

Wednesday, October 28

Drug Discovery TodayOct 28

Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: what target-modality-formulation matching explains

ReviewType 2 diabetes

Paper

Tuesday, October 27

PharmaceuticsOct 27

Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective

Representative structural frameworks of approved and investigational anti-obesity agents.

ReviewObesity

Paper

Tuesday, October 20

Obesity PillarsOct 20

Determinants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity

ReviewGLP-1 receptor agonists

Paper

Monday, October 19

Journal of the American Society of NephrologyOct 19

Glucagon-Like Peptide-1 Receptor Agonists and Multi-hormone Receptor Modulators for Kidney Protection in Nondiabetic Kidney Disease

ReviewGLP-1 receptor agonists

Paper

Wednesday, October 7

American Heart JournalOct 7

Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)

Trial protocolCardiovascular disease

Paper

Thursday, October 1

Diabetes, Metabolic Syndrome and ObesityOct 1

Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review

PRISMA flow diagram for the literature search.

Systematic review of studies in peopleObesity

Paper

Tuesday, September 29

Diabetes TherapySep 29

New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus

ReviewObesity

Paper

Wednesday, September 16

Cardiology in ReviewSep 16

Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide

ReviewInterventions

Paper

Tuesday, September 8

Preprints.orgSep 8

Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication Opportunities

Preprint: cohort study of 761 peopleInterventions

Paper

Wednesday, September 2

Diabetes, Obesity & MetabolismSep 2

Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning

ReviewInterventions

Paper

Tuesday, August 18

Naunyn-Schmiedeberg's Archives of PharmacologyAug 18

Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials

Meta-analysis of randomized trialsInterventions

Paper

Wednesday, August 12

Annals of Medicine and SurgeryAug 12

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo

Meta-analysis of randomized trialsObesity

Paper

Tuesday, August 4

EndocrinologyAug 4

Physical activity and human islet amyloid polypeptide islet amyloidosis: mechanistic plausibility, missing evidence, and future directions

ReviewMechanisms

Paper

Friday, July 31

LancetJul 31

Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

Randomized trial in 262 peopleType 2 diabetes

Paper

LancetJul 31

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

Randomized trial in 186 peopleType 2 diabetes

Paper

Thursday, July 30

Preprints.orgJul 30

From the Incretin System to the Entero–Pancreatico–Hepatico–Systemic Polyhormonal Metabolic Homeostasis Network

Preprint: reviewGLP-1 and incretin signaling

Paper

Thursday, July 2

Ageing Research ReviewsJul 2

Amylin at the crossroads of type 2 diabetes and neurodegenerative diseases

ReviewMechanisms

Paper

Saturday, June 6

ADA Scientific Sessions 2026 AbstractJun 6

Petrelintide, a Human Amylin Analog for the Treatment of Obesity: Efficacy and Safety from the Phase 2 Trial, ZUPREME 1

Randomized trial in 485 peopleObesity

Paper

Saturday, March 28

International Journal of Molecular SciencesMar 28

Physiological Implications of Pancreatic Amyloid Polypeptide Aggregation and Its Inhibition by Melatonin

ReviewMechanisms

Paper

Thursday, March 19

Journal of Cachexia, Sarcopenia and MuscleMar 19

Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro

Experiments in mouse cellsMuscle

Paper

MetabolismMar 19

Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives

ReviewObesity

Paper

Wednesday, March 11

Endocrine ReviewsMar 11

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity

ReviewObesity

Paper

Tuesday, February 24

PeptidesFeb 24

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes

ReviewInterventions

Paper

Friday, January 30

Nephrology, Dialysis, TransplantationJan 30

GLP-1-based therapeutics for cardiorenal protection in metabolic diseases

ReviewInterventions

Paper

Monday, January 19

Journal of Obesity & Metabolic SyndromeJan 19

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity

ReviewInterventions

Paper

Wednesday, January 14

LancetJan 14

Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits

ReviewInterventions

Paper

Wednesday, November 26

Clinical and Molecular HepatologyNov 26

Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders

ReviewGLP-1 receptor agonists

Paper

Monday, September 29

Nephrology, Dialysis, TransplantationSep 29

How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA

CommentaryChronic kidney disease

Paper

Friday, September 19

Clinical PharmacologySep 19

Pharmacotherapy for Obesity: Recent Updates

ReviewObesity

Paper

Tuesday, August 26

Medicina ClinicaAug 26

Weight management treatment in obesity

ReviewObesity

Paper